Insider · CIK 0001413350
Jay Venkatesan
director
Files at ELTX (Elicio Therapeutics, Inc.), SER (Serina Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | ELTX Elicio Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +21,750 | $0.00 | $0 | 21,750 | 40 d ago |
| May 19, 2025 | ELTX Elicio Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +7,900 | $0.00 | $0 | 7,900 | May 20, 2025 |
| Apr 8, 2025 | SER Serina Therapeutics, Inc. | AGrant or award Series A Convertible Preferred Stockderivativeindirect: The Jay Venkatesan Legacy Trust | +96,525 | $5.18 | $500k | 96,525 | Apr 10, 2025 |
| Nov 26, 2024 | ELTX Elicio Therapeutics, Inc. | XIn-the-money exercise Common Stock | +50,000 | $0.01 | $500 | 179,581 | Nov 29, 2024 |
| Nov 26, 2024 | ELTX Elicio Therapeutics, Inc. | XIn-the-money exercise Warrant to Purchase Common Stockderivative | -50,000 | $0.00 | $0 | 0 | Nov 29, 2024 |
| Nov 21, 2024 | ELTX Elicio Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +4,100 | $0.00 | $0 | 4,100 | Nov 25, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.